Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Oct 6, 2025

Hamid Ghanadan, CEO of LINUS, discusses the findings of the company's recent state-of-the-science research, a semiannual survey that tracks sentiment and confidence within the life sciences. Notably, a growing gap in optimism exists between academic and biopharma scientists.  As a result, academics are seeking partnerships at a new level due to economic pressures from grant cancellations, the need for multidisciplinary collaboration to solve complex problems, and the desire for a stronger collective voice. AI was identified as the top priority for academia and biopharma, as is the need to improve communication with the public about scientific discoveries and medical advancements.

Hamid explains, "We started the state-of-the-science research four years ago, so this is the eighth time that we've done it. And what we're really doing is measuring consumer confidence within the life sciences. So we track sentiment, we track funding, we track barriers and opportunities, as well as purchase intentions. And we do it every six months for the coming six months of the year."  

"So here you have to take into consideration that we talk to scientists globally in this survey, and we talk to them from a variety of different settings and environments. So while about half of our respondents are from academic institutions around the world, the other half are in a variety of industries, mostly biopharma. And we see here that there's a shift, there's a difference in sentiment and in optimism, in outlook, in interest in science, in the applicability of science, and how these different groups are managing it. As you can imagine, the academics are feeling a lot more pressure."  

"The consumer sentiment is lower, and there's definitely more fear in that cohort of scientists. Biopharma is actually surprisingly more resilient, more forward-looking. So on the biopharma side, what we're seeing is that there's actually surprising resilience and there's forward-looking intentions. And we see that scientists are actually looking forward to applying new techniques and new technologies that are coming online, and they have more confidence in their ability to make progress for the second half of 2025." 

 #LINUSGroup #Lifesciences #Healthcare #AIHealthcare #Stategy #Scientists #AI #MedAI

thelinusgroup.com

Listen to the podcast here

LINUS